Healthyhorns is proud to be part of one of the world’s largest research institutions where discovery — expanding knowledge and human understanding — is a core value.
Antidepressant Study: Re-EMBARC
Antidepressant Study: Re-EMBARC (Establishing Multi-Modal Brain Biomarkers Using Data-driven Analytics for Treatment Selection in Depression)
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. The researchers at the Fonzo Lab in the Psychiatry Dept. at Dell Med will measure brain function during completion of certain behavioral tasks inside an fMRI scanner and using a device called an electroencephalogram (EEG) to measure electrical activity in the brain with scalp electrodes.
Eligibility criteria for Qualified participants:
Are diagnosed with Major Depressive Disorder, have experienced major depression, and/or are currently having symptoms of depression (diagnosis not required)
Are 18-65 years old and fluent in English
Are willing to undergo MRI and EEG procedures to measure brain function
Are willing to take an FDA-approved, once-daily medication for treating depression
Can visit the laboratory several times over the course of an 8-10 week period, approximately 11 times in an in-person/virtual hybrid fashion
Qualified participants receive:
Free psychiatric consultation and monitoring, free Sertraline (Zoloft) prescription, and compensation of up to $550